| Literature DB >> 27835963 |
Vivienne Helaine Chuter1,2, Angela Searle3, Martin J Spink1.
Abstract
BACKGROUND: Foot pain is a common problem affecting up to 1 in 5 adults and is known to adversely affect activities of daily living and health related quality of life. Orthopaedic footwear interventions are used as a conservative treatment for foot pain, although adherence is known to be low, in part due to the perception of poor comfort and unattractiveness of the footwear. The objective of this trial was to assess the efficacy of flip-flop style footwear (Foot Bio-Tec©) with a moulded foot-bed in reducing foot pain compared to participant's usual footwear.Entities:
Keywords: Health status indicators; Pain measurement; Shoes
Mesh:
Year: 2016 PMID: 27835963 PMCID: PMC5106832 DOI: 10.1186/s12891-016-1327-x
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Fig. 1Test Footwear: Foot Bio-Tec© Orthotic footwear
Fig. 2Flow of participants through the randomised controlled trial
Participant characteristics at baseline
| Characteristic | Control ( | Flip-Flop ( |
|---|---|---|
| Sex | Male 23 (43) | Male 27 (50) |
| Female 31 (57) | Female27 (50) | |
| Age (mean ± SD in years) | 49.1 ± 16.9 | 48.6 ± 14.1 |
| Duration of foot pain (mean ± SD in weeks) | 71.3 ± 179.3 | 63.5 ± 163.4 |
| Location of pain | ||
| Rearfoot | 11 (20) | 15 (28) |
| Midfoot | 12 (22) | 11 (20) |
| Forefoot | 22 (41) | 18 (33) |
| General foot | 9 (17) | 10 (19) |
| Does regular exercise | 49 (87) | 47 (85) |
| Medical Conditionsa | ||
| Diabetes | 3 (5.5) | 8 (14.8) |
| Osteoarthritis | 12 (22.2) | 10 (18.5) |
| High blood pressure | 24 (44.4) | 23 (42.6) |
| Heart disease | 4 (7.4) | 5 (9.3) |
| Lung disease | 6 (11.1) | 2 (3.7) |
| Hormone replacement therapy | 0 (0) | 3 (5.5) |
| Hypercholesterolemia | 16 (29.6) | 23 (42.6) |
| Rheumatoid arthritis | 1 (1.9) | 2 (3.7) |
| Back pain | 8 (14.8) | 11 (20.4) |
| Depression | 5 (9.3) | 5 (9.3) |
Values are number (%) unless otherwise statedaSome participants reported multiple medical conditions
Primary and secondary outcome measures of pain and function at baseline and 12 week follow-up. Values are means (standard deviations) unless otherwise stated
| Measure | Intervention Group | Control group | Adjusted mean difference (95 % CI) |
| Effect size (Cohen’s d) | ||
|---|---|---|---|---|---|---|---|
| Baseline | Follow-up | Baseline | Follow-up | ||||
| Primary Outcome | |||||||
| FHSQ Painb | 52.6 (15.7) | 61.5 (16.4) | 51.1 (16.7) | 50.7 (17.6) | 9.6 (5.5 to 13.3) | <0.01 | 0.64 |
| Secondary Outcomes | |||||||
| Pain VAS (mm)c | 55.7 (17.9) | 45.4 (19.6) | 52.7 (18.3) | 51.8 (20.5) | −9.4a (5.6 to 13.2) | <0.01 | 0.33 |
| FHSQ Functionb | 60.7 (20.4) | 68.1 (19.4) | 60.0 (20.2) | 59.1 (21.4) | 8.4a (4.8 to 11.7) | <0.01 | 0.44 |
| FHSQ General Foot Healthb | 26.5 (27.9) | 36.7 (30.7) | 23.8 (27.0) | 25.1 (27.0) | 8.9a (0.6 to 13.3) | <0.01 | 0.41 |
ameets minimal important difference level for a clinically meaningful difference
bFHSQ_Foot Health Status Questionnaire (0 = “worst foot health,” 100 = “best foot health”)
cVAS_Visual Analog Scale (0 to 100 - higher values indicate greater levels of pain)